Cambridge, MA, USA & Rostock, Germany – February 25, 2020 – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced the appointment of Dr. Vaibhav Joshi to the newly created role of Chief Data Officer. Dr. Vaibhav Joshi, reporting to Dr. V. Weckesser, CIO, will be responsible for ensuring that the organization, quality, management, and commercial models of the Company’s data-based knowledge follows best practice and uses the newest and most innovative algorithms.
"We are extremely pleased to have Dr. Joshi join CENTOGENE's Leadership Team, bringing a proven track record and a unique combination of medical and data-based experience across several therapeutic areas," stated Dr. Weckesser. "His role underscores the importance of our data repository in driving diagnostic solutions and supporting our pharmaceutical partners while marking a significant milestone in the Company’s growth and providing our patients with high-quality, knowledge-driven medical solutions."
Dr. Joshi joins CENTOGENE from Virgin Care, a leading provider of more than 400 health and social care services across the United Kingdom, where he served as Chief Data Officer. Prior to Virgin Care, Vaibhav served as Clinical Informatics Director at the Private Healthcare Information Network and Clinical Analytics Lead at Ramsay Health Care UK. Dr. Vaibhav Joshi holds a Doctor of Medicine and has over ten years of clinical experience in NHS working in diverse therapeutics areas. He also holds an MBA from Imperial College London and is a Founding Fellow of the Faculty of Clinical Informatics as well as a Certified Information Systems Security Professional.
"I'm honored to join CENTOGENE and am committed to making a strong and comprehensive impact on the lives of patients living with rare genetic diseases. I look forward to lending my expertise to the global knowledge repository CENTOGENE has built in support of high-quality global solutions for the benefit of all rare disease patients."